- ACT
Artemisinin combination therapy
- AED
United Arab Emirates Dirham
- API
Active pharmaceutical ingredient
- CDR
Common Drug Review (Canada)
- CEF
Cyclophosphamide, epirubicin, fluorouracil
- CIF
Cost, insurance, and freight
- CMF
Cyclophosphamide, methotrexate, fluorouracil
- DALY
Disability-adjusted life year
- ERP
External reference pricing
- GDP
Gross domestic product
- GFATM
Global Fund to Fight AIDS, Tuberculosis and Malaria
- GRADE
Grading of Recommendations Assessment, Development and Evaluation
- HAI
Health Action International
- HIC
High-income country
- HITAP
Health Intervention and Technology Assessment Program
- HTA
Health technology assessment
- ICER
Incremental cost-effectiveness ratio
- INN
International nonproprietary name
- IRP
Internal reference pricing
- LAC
Latin American and Caribbean
- LIC
Low-income country
- L-MIC
Lower-middle-income country
- LMICs
Low- and middle-income countries
- LPG
Lowest priced generic
- MSP
Manufacturer's selling price
- NHIS
National Health Insurance
- NHS
National Health Service (UK)
- NICE
National Institute for Clinical Excellence (UK)
- OB
Originator brand
- OECD
Organisation for Economic Co-operation and Development
- OTC
Over-the-counter
- PBAC
Pharmaceutical Benefits Advisory Committee (Australia)
- PPRI
Prescription pricing and reimbursement information
- QALY
Quality-adjusted life year
- RDF
Revolving drug fund
- SNS
Sistema Nacional de Salud (Spain)
- SAARC
South Asian Association for Regional Cooperation
- SP
Sulfadoxine-pyrimethamine
- TRIPS
Trade-related aspects of intellectual property
- UMIC
Upper-middle-income country
- VAT
Value-added tax
- WTO
World Trade Organization
- ZAR
South Africa Rand
